The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number:3235-0006
Expires:Oct 31, 2018
Estimated average burden
hours per response:23.8

COLUMN 1COLUMN 2COLUMN 3COLUMN 4COLUMN 5COLUMN 6COLUMN 7COLUMN 8
VALUESHRS ORSH/PUT/INVESTMENTOTHERVOTING AUTHORITY
NAME OF ISSUERTITLE OF CLASSCUSIP(x$1000)PRN AMTPRNCALLDISCRETIONMANAGERSOLESHAREDNONE
Revolution Medicines IncCOM76155X10017,475685,011SH SOLE 685,01100
RAPT Therapeutics IncCOM75382E1093,197145,401SH SOLE 145,40100
NGM Biopharmaceuticals IncCOM62921N10519,8081,298,908SH SOLE 1,298,90800
Nurix Therapeutics IncCOM67080M1034,583327,123SH SOLE 327,12300